Cellectis S.A. (LON:0WA2)
2.910
-0.180 (-5.83%)
At close: Nov 3, 2025
Cellectis Revenue
Cellectis had revenue of $18.19M USD in the quarter ending June 30, 2025, with 91.44% growth. This brings the company's revenue in the last twelve months to $63.44M, up 223.09% year-over-year. In the year 2024, Cellectis had annual revenue of $49.22M with 435.37% growth.
Revenue (ttm)
$63.44M
Revenue Growth
+223.09%
P/S Ratio
4.00
Revenue / Employee
$285.76K
Employees
222
Market Cap
185.26M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 49.22M | 40.02M | 435.37% |
| Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
| Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
| Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
| Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shell | 200.18B |
| BP p.l.c. | 138.32B |
| Unilever | 51.24B |
| HSBC Holdings | 43.13B |
| AstraZeneca | 41.24B |
| Rio Tinto Group | 39.22B |
| GSK plc | 32.17B |
| British American Tobacco p.l.c. | 25.60B |